Takeda and its alliance partners are committed to improving patient care by supporting scientific advances in medicine and increasing our understanding of important diseases. As part of this commitment, the Investigator Initiated Research Studies (IISR) program supports innovative clinical and basic science studies that address important medical and scientific questions related to our compounds and therapeutic areas of interest.

An IISR is defined as an unsolicited, independent, pre/non-clinical, clinical, outcomes, or disease state research study where the Investigator, organization or institution (academic, private, or governmental) serves as the Sponsor, and Takeda provides support in the form of funding, study drug, and/or authorization to reference Takeda's NDA or other regulatory submissions (e.g., IND).

Visit Takeda.com (研究者主導研究申請プログラムに関してはこちらから) for further information about our products and therapeutic areas of interest.

Please note: For oncology pre-clinical requests only, Takeda is not currently accepting proposals for pre-clinical research on oncology clinical-stage molecules.

This will affect pre-clinical requests for: VELCADE, ADCETRIS, Brigatinib, Pevonedistat, Ixazomib, Ponatinib, TAK-228, TAK-243, TAK-659, TAK-788, TAK-931 and TAK-981. All other submissions are welcome.

Support for IISRs may be publicly disclosed in accordance with all local laws and regulations.
US Physicians may refer to the Ethical Exchange Brochure or the Centers for Medicare and Medicaid Services for more information.

Please be aware that support is awarded strictly based on research merit criteria.
Submission of a proposal does not imply or guarantee approval. Support of a study in no way implies any obligation toward or is any way connected to the recommendation or prescribing of products.

Use and access of this site is subject to the Terms of Use & Privacy Policy.